Gene · 4593
Papers3,141
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 3,141
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Clinical Issue of Myasthenia Gravis Related to Immune Checkpoint Inhibitors. | Curr Oncol Rep | 2024 | 38954314 | PubTator, text mining | PubMed |
| Heterogeneous Presentations and Serologies in Myasthenia Gravis Patients Presenting with Dysphagia. | Laryngoscope | 2024 | 38949061 | PubTator, text mining | PubMed |
| Case report: Rapid clinical improvement in acute exacerbation of MuSK-MG with efgartigimod. | Front Immunol | 2024 | 38911858 | PubTator, text mining | PubMed |
| Advancements and prospects of novel biologicals for myasthenia gravis: toward personalized treatment based on autoantibody specificities. | Front Pharmacol | 2024 | 38881870 | PubTator, text mining | PubMed |
| Free essential amino acid feeding improves endurance during resistance training via DRP1-dependent mitochondrial remodelling. | J Cachexia Sarcopenia Muscle | 2024 | 38881251 | PubTator, text mining | PubMed |
| Advances in Understanding and Managing Myasthenia Gravis: Current Trends and Future Directions. | Cureus | 2024 | 38803727 | PubTator, text mining | PubMed |
| Treating myasthenia gravis beyond the eye clinic. | Eye (Lond) | 2024 | 38789789 | PubTator, text mining | PubMed |
| MuSK Antibody-Positive Myasthenia Gravis With SARS CoV-2 Infection: A Case Report and Literature Review. | J Clin Neuromuscul Dis | 2024 | 38771234 | PubTator, text mining | PubMed |
| Acetylcholinesterase inhibitors are ineffective in MuSK-antibody positive myasthenia gravis: Results of a study on 202 patients. | J Neurol Sci | 2024 | 38759248 | PubTator, text mining | PubMed |
| Myasthenia Gravis Disease Burden and Its Impact on Satisfaction with Life: A Qualitative Survey of Patients' Perspectives in Japan. | Neurol Ther | 2024 | 38748320 | PubTator, text mining | PubMed |
| [Muscle-Specific Receptor Tyrosine Kinase Antibody Positive Myasthenia Gravis]. | Brain Nerve | 2024 | 38741505 | PubTator, text mining | PubMed |
| The MuSK agonist antibody protects the neuromuscular junction and extends the lifespan in C9orf72-ALS mice. | Mol Ther | 2024 | 38734896 | PubTator, text mining | PubMed |
| A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression. | Front Immunol | 2024 | 38715598 | PubTator, text mining | PubMed |
| Exploring the depths of IgG4: insights into autoimmunity and novel treatments. | Front Immunol | 2024 | 38698867 | PubTator, text mining | PubMed |
| Building, Breaking, and Repairing Neuromuscular Synapses. | Cold Spring Harb Perspect Biol | 2024 | 38697654 | PubTator, text mining | PubMed |
| Congenital myasthenic syndromes in adults: clinical features, diagnosis and long-term prognosis. | Brain | 2024 | 38696726 | PubTator, text mining | PubMed |
| Change of voltage-gated sodium channel repertoire in skeletal muscle of a MuSK myasthenia gravis mouse model. | Eur J Neurosci | 2024 | 38650308 | PubTator, text mining | PubMed |
| Markedly upregulated serum semaphorin 4A as a novel activity marker of myasthenia gravis. | Scand J Immunol | 2024 | 38605547 | PubTator, text mining | PubMed |
| Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis. | J Neurol | 2024 | 38578496 | PubTator, text mining | PubMed |
| Clinical Features and Prognostic Analysis of MuSK-Antibody-Positive Myasthenia Gravis versus Double-Seropositive Myasthenia Gravis: A Single-Center Study from Central South China. | Neuropsychiatr Dis Treat | 2024 | 38566882 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4593/papers?page=13